V. Backer (Copenhagen, Denmark), A. Bossios (Gothenburg, Sweden)
Effects of airborne pollen levels on drug consumption for seasonal allergic rhinoconjunctivitis: A ten-year French study
D. Caillaud, S. Martin, C. Segala, P. Vidal, J. Lecadet, P. Rouzaire, A. Tridon, J. P. Besancenot, M. Thibaudon, B. Evrard (Clermont-Ferrand, Baud, Brussieu, France)
|  |
Comparative efficacy of different groups of drugs for the treatment of bronchial asthma in combination with allergic rhinitis
N. Zhukova, M. Zakharova, O. Krjuchkova (Simferipol, Ukraine)
| |
Therapeutic effectpredictors during sublingual immunotherapy for Japanese seasonal allergic rhinitis
T. Yamada, M. Sakashita, Y. Imoto, S. Fujieda (23-3 Matsuoka-Shimoaizuki, Yoshida, Japan)
| |
Dynamic change of house dust mites and its components- sIgE and sIgG4 in specific immunotherapy
P. Zheng, B. Sun, G. Zeng, W. Luo, H. Huang, B. Sun (Guangzhou, China)
|  |
Autoimmune disorders in allergen immunotherapy, allergic rhinitis, and non-allergic patients
D. B. Esposito, L. Nelsen, J. C. L. Hawes, C. N. Holick, J. Maloney, V. Mehta, D. Mines, G. Pianka, S. F. Lanes (Andover, Whitehouse Station, United States Of America)
| |
Outcomes of immunotherapy of patients with COPD
S. Farkhutdinov, U. Farkhutdinov (Ufa, Russian Federation)
| |
Subcutaneous allergen specific immunotherapy and immunological response in patients with bronchial asthma and allergic rhinitis in India
R. Kumar, N. Gupta, J. Mittal (Delhi, Dehi, India)
| |
The impact of sublingual allergen-specific therapy on asthma control and quality of life
D. Nagatkin, Z. Alexandr, J. Bogdanova, O. Nagatkina (Samara, Russian Federation)
| |
Patterns of clinical use of omalizumab in Spain: A 5-year "real-life" study
L. Pérez de Llano, J. M. Zubeldia, L. Herráez (Lugo, Madrid, Barcelona, Spain)
| |
Demographic, clinical and health care resource utilisation characterisation of patients prescribed omalizumab: A retrospective, real world data study
M. Baldwin, G. Machnicki, L. Li, Z. Wei, T. C. Yu, K. H. Kahler (Horsham, West Sussex, United Kingdom; Buenos Aires, Argentina; Jiaxing, Zhejiang Province, China; East Hanover, United States Of America)
| |
Omalizumab reduces exacerbations and healthcare utilisation in severe allergic asthma patients UK clinical practice - APEX II study
A. Menzies-Gow, M. Masoli, L. Heaney, C. Corrigan, F. De Iorio, R. Niven (London, Derriford, Belfast, Frimley, Manchester, United Kingdom)
| |
Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies
I. Kasujee, G. Bader (Basel, Switzerland)
| |
Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study
D. Saralaya, A. Menzies-Gow, I. Clifton, A. H. Mansur, A. Hart-Thomas, R. Niven (Bradford, London, Leeds, Birmingham, Huddersfield, Manchester, United Kingdom)
| |
Unexpected severe systemic allergic reaction after hymenoptera sting in well controlled asthma during treatment with omalizumab
G. Guarnieri, P. Bonadonna, M. Schiappoli, P. Maestrelli (Padova, Verona, Italy)
| |
Optimal technique for measuring the IgE blocked by omalizumab
C. Domingo, A. Sogo, J. F. Delgado, M. Bosque, X. Domingo, D. R. Monserrate, M. Ollert, M. J. Amengual (Sabadell, Spain; München, Germany)
| |
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
J. Bousquet, S. Rao, V. Manga (Montpellier, France; Basel, Switzerland)
| |
Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study
R. Niven, C. Bucknall, R. Chaudhuri, R. Kurukulaaratchy, F. De Iorio, A. Menzies-Gow (Manchester, Glasgow, Southampton, Frimley, London, United Kingdom)
| |
Evaluating omalizumab persistency of response after long-term therapy (XPORT)
W. Busse, B. Trazskoma, T. Omachi, J. Canvin, K. Rosén, B. Chipps, A. Luskin, P. Solari (Madison, South San Francisco, Sacramento, United States Of America; Horsham, United Kingdom)
| |